During the molecular tumor board discussion, the identified RAD51B loss-of-function mutation was recognized as the primary actionable target, conferring a “BRCAness” phenotype and predicting sensitivity to PARP inhibitors. The gene discussed is RAD51B; the disease is neoplasm.